Thelansis

  Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural surface, predominantly caused by prior asbestos exposure. Most MPM cases are caused by exposure to asbestos, often occurring >40 years previously. Prognosis with MPM is poor, and median survival ranges from 8 to 14 months after diagnosis. Women have a better prognosis than men, but due to the occupational nature of the disease, there is a 4:1 male predominance. The four major histological subtypes are Sarcomatoid, epithelioid, biphasic or mixed, and desmoplastic. The sarcomatoid variant is associated with the worst outcomes, with a four-month median survival.   The incidence of malignant pleural mesothelioma (MPM) ranges between 9 to 23 points per MN elderly patient with a man and women of 5:1.2.   The competitive landscape of Malignant Pleural Mesothelioma (MPM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelera...